Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective β3 adrenergic receptor agonist antiobesity agents

被引:22
作者
Biftu, T [1 ]
Feng, DD
Liang, GB
Kuo, H
Qian, XX
Naylor, EM
Colandrea, VJ
Candelore, MR
Cascieri, MA
Colwell, LF
Forrest, MJ
Hom, GJ
MacIntyre, DE
Stearns, RA
Strader, CD
Wyvratt, MJ
Fisher, MH
Weber, AE
机构
[1] Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA
[2] Merck Res Labs, Dept Biochem & Physiol, Rahway, NJ 07065 USA
[3] Merck Res Labs, Dept Drug Metab, Rahway, NJ 07065 USA
[4] Merck Res Labs, Dept Pharmacol, Rahway, NJ 07065 USA
[5] Merck Res Labs, Dept Comparat Med, Rahway, NJ 07065 USA
关键词
D O I
10.1016/S0960-894X(00)00268-7
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Benzyl and phenoxymethylene substituted oxadiazoles are potent and orally bioavailable beta(3) adrenergic receptor (AR) agonists. The 4-trifluormethoxy substituted 5-benzyl oxadiazole 5f has an EC50 of 8 nM in the beta(3) AR agonist assay with 100-fold selectivity over beta(1) and beta(2) AR binding inhibition activity. Its oral bioavailability in dogs is 30 +/- 4%, with a half-life of 3.8 +/- 0.4 h. In the anesthetized rhesus, 5f evoked a dose-dependent glycerolemia (ED50Gly = 0.15 mg/kg): Under these conditions a heart rate increase of 15% was observed at a dose level of 10 mg/kg. (C) 2000 Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1431 / 1434
页数:4
相关论文
共 4 条
[1]  
BOUALEM O, 1995, SYNTHETIC COMMUN, P1451
[2]   Discovery of an orally bioavailable alkyl oxadiazole β3 adrenergic receptor agonist [J].
Feng, DQD ;
Biftu, T ;
Candelore, MR ;
Cascieri, MA ;
Colwell, LF ;
Deng, LP ;
Feeney, WP ;
Forrest, MJ ;
Hom, GJ ;
MacIntyre, DE ;
Miller, RR ;
Stearns, RA ;
Strader, CD ;
Tota, L ;
Wyvratt, MJ ;
Fisher, MH ;
Weber, AE .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (13) :1427-1429
[3]   An improved oxadiazole synthesis using peptide coupling reagents [J].
Liang, GB ;
Feng, DD .
TETRAHEDRON LETTERS, 1996, 37 (37) :6627-6630
[4]  
MERCK CO INC, 1997, Patent No. 9746556